WallStSmart

Adapthealth Corp (AHCO)vsAstraZeneca PLC (AZN)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

AstraZeneca PLC generates 1710% more annual revenue ($58.74B vs $3.24B). AZN leads profitability with a 17.4% profit margin vs -2.2%. AZN earns a higher WallStSmart Score of 64/100 (C+).

AHCO

Hold

40

out of 100

Grade: F

Growth: 4.0Profit: 3.5Value: 6.7Quality: 3.5
Piotroski: 3/9Altman Z: 0.99

AZN

Buy

64

out of 100

Grade: C+

Growth: 6.7Profit: 8.0Value: 5.3Quality: 5.0
Piotroski: 6/9Altman Z: 1.48
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHCOUndervalued (+83.4%)

Margin of Safety

+83.4%

Fair Value

$63.51

Current Price

$13.11

$50.40 discount

UndervaluedFair: $63.51Overvalued
AZNUndervalued (+4.1%)

Margin of Safety

+4.1%

Fair Value

$214.51

Current Price

$184.74

$29.77 discount

UndervaluedFair: $214.51Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHCO1 strengths · Avg: 10.0/10
Price/BookValuation
1.1x10/10

Reasonable price relative to book value

AZN5 strengths · Avg: 9.0/10
Market CapQuality
$287.11B10/10

Mega-cap, among the largest globally

EPS GrowthGrowth
53.9%10/10

Earnings expanding 53.9% YoY

Return on EquityProfitability
22.8%9/10

Every $100 of equity generates 23 in profit

Operating MarginProfitability
21.6%8/10

Strong operational efficiency at 21.6%

Free Cash FlowQuality
$1.38B8/10

Generating 1.4B in free cash flow

Areas to Watch

AHCO4 concerns · Avg: 2.8/10
Market CapQuality
$1.78B3/10

Smaller company, higher risk/reward

Debt/EquityHealth
1.183/10

Elevated debt levels

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-4.3%2/10

ROE of -4.3% — below average capital efficiency

AZN4 concerns · Avg: 3.5/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
27.9x4/10

Moderate valuation

Revenue GrowthGrowth
4.1%4/10

4.1% revenue growth

Altman Z-ScoreHealth
1.482/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : AHCO

The strongest argument for AHCO centers on Price/Book.

Bull Case : AZN

The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.

Bear Case : AHCO

The primary concerns for AHCO are Market Cap, Debt/Equity, Piotroski F-Score.

Bear Case : AZN

The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.

Key Dynamics to Monitor

AHCO profiles as a turnaround stock while AZN is a value play — different risk/reward profiles.

AHCO carries more volatility with a beta of 1.50 — expect wider price swings.

AZN is growing revenue faster at 4.1% — sustainability is the question.

AZN generates stronger free cash flow (1.4B), providing more financial flexibility.

Bottom Line

AZN scores higher overall (64/100 vs 40/100), backed by strong 17.4% margins. AHCO offers better value entry with a 83.4% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adapthealth Corp

HEALTHCARE · MEDICAL DEVICES · USA

AdaptHealth Corp. The company is headquartered in Plymouth Meeting, Pennsylvania.

Visit Website →

AstraZeneca PLC

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.

Want to dig deeper into these stocks?